Title: High proportion of post-acute sequelae of SARS-CoV-2 infection in individuals 1-6 months after illness and association with disease severity in an outpatient telemedicine population

Authors:

James B. O’Keefe, Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

H. Caroline Minton, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA

Mary Morrow, Emory Healthcare, Atlanta, Georgia, USA

Colin Johnson, Department of General Surgery, Emory Bariatric Clinic, Emory Healthcare, Atlanta, GA, USA

Miranda A. Moore, Department of Family and Preventive Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Ghazala A. D. O’Keefe, Section of Vitreoretinal Surgery and Diseases, Section of Uveitis and Vasculitis, Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA

Karima Benameur, Department of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA

Jason Higdon, Division of General Internal Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Jessica K. Fairley, Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA

Keywords: COVID-19, SARS-CoV-2, PASC, prolonged, symptoms

Running title: PASC in Outpatients with COVID-19

Corresponding Author:

James B. O’Keefe

Emory Clinic A, 1365 Clifton Road NE Atlanta, GA 30322, USA

Abstract

Background

Individuals with coronavirus disease 2019 (COVID-19) may have persistent symptoms following their acute illness. The prevalence and predictors of these symptoms, termed post-acute sequelae of SARS-CoV-2 (PASC), are not fully described.

Methods

Participants discharged from an outpatient telemedicine program for COVID-19 were emailed a survey (1-6 months after discharge) about ongoing symptoms, acute illness severity, and quality of life. Standardized telemedicine notes from acute illness were used for covariates (comorbidities and provider-assessed symptom severity). Bivariate and multivariable analyses were performed to assess predictors of persistent symptoms.

Results

Two hundred and ninety patients completed the survey, of whom 115 (39.7%) reported persistent symptoms including fatigue (n= 59, 20.3%), dyspnea on exertion (n=41, 14.1%), and mental fog (n=39, 13.5%) among others. Proportion of persistent symptoms did not differ based on duration since illness (<90 days: n=32, 37.2% versus $\geq$ 90 days: n=80, 40.4%, p = 0.61). Predictors of persistent symptoms included provider-assessed moderate-severe illness (aOR 3.24, 95% CI 1.75, 6.02), female sex (aOR 1.99 95% CI 0.98, 4.04; >90 days out: aOR 2.24 95% CI 1.01, 4.95), and middle age (aOR 2.08 95% CI 1.07, 4.03). Common symptoms associated with reports of worse physical health included weakness, fatigue, myalgias, and mental fog.

Conclusions

Symptoms following acute COVID-19 are common and may be predicted by factors during the acute phase of illness. Fatigue and neuropsychiatric symptoms figured prominently. Select symptoms seem to be particularly associated with perceptions of physical health following COVID-19 and warrant specific attention on future studies of PASC.

Introduction

In response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, health systems in the United States rapidly reorganized in March 2020 to create home monitoring programs (1). The resulting systems did not anticipate prolonged symptoms following acute coronavirus disease 2019 (COVID-19) until reports arose in personal accounts and social media (2). Subsequent evidence emerged that persistent symptoms are common for both hospitalized (3) and non-hospitalized (4) cohorts, and these patients have described challenges with stigma as well as difficulty accessing care for their symptoms (5). Later reports indicate disruption to usual activities and impaired quality of life may last months (6–8). Studies of survivors of severe acute respiratory syndrome (SARS) hospitalized from 2001-2003 showed persistent pulmonary dysfunction (9) as well as chronic fatigue and psychiatric illnesses (10) lasting years. Other viral illnesses have varied post-acute syndromes including Ebola (11), Chikungunya (12), and dengue (13). Preliminary data for SARS-CoV-2 demonstrate a clear need to characterize the chronic course of this illness. In addition to understanding predictors of chronic COVID-19, understanding the long-term impact on individuals' health and wellbeing will inform future standards of care for treating patients with COVID-19.

Descriptions of the clinical syndrome of “long COVID” or “post-acute sequelae of SARS-CoV-2 infection” (PASC) have defined symptoms greater than 3 weeks as “post-acute COVID” and greater than 12 weeks as “chronic COVID” (14,15). The underlying pathophysiology is not clear, with studies highlighting possible roles of elevated inflammatory markers, lung dysfunction, muscle weakness, and brain positron emission tomography hypometabolism (16–20). One

report using quantitative magnetic resonance imaging could not link specific symptoms to specific organ impairment (21). A meta-analysis of 47,910 patients found the most frequent symptoms include fatigue, headache, attention disorder, hair loss, and dyspnea (22) and noted a high degree of heterogeneity in published studies with a need for future studies to stratify results by patient baseline characteristics and disease severity. Individual cohort studies have reported a variety of specific risk factors for prolonged symptoms including female sex (23–25), higher body mass index (BMI) (23,24), middle age (26), older age (24,27), underlying autoimmunity (8), while one study found no significant predictors (28). Features of acute COVID-19 may predict PASC, with cohort studies finding increasing risk for: patients with more than 5 acute symptoms (24), presence of specific acute symptoms (chest pain, fatigue, fever, olfactory impairment, headaches, or diarrhea) (25), and hospitalization (26).

We previously described duration of symptoms in acute COVID-19 in a telemedicine cohort, and found they were significantly associated with the severity of symptoms at initial medical evaluation (5-6 days after onset) (29). We also noted a higher rate of asthma amongst patients with requiring ongoing telemedicine care for symptoms beyond 6 weeks (42%) compared to the whole cohort (13%) (30). We hypothesize that initial symptom severity as well as select comorbidities such as asthma will also predict prolonged symptoms (>90 days). Lastly, using modified quality of life questions, we explored which persistent symptoms were associated with lower ratings of physical and emotional health.

Methods

Study population

Our study population consisted of patients enrolled in Emory Healthcare's Virtual Outpatient Management Clinic (VOMC) in Atlanta, Georgia between March 24 and September 20, 2020. Patients were offered enrollment in VOMC during results notification calls following a positive SARS-CoV-2 nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR) test at an Emory site (two large throughput outpatient testing centers and the emergency departments of four acute care hospitals). Patients who received a positive test at an outside site (rapid test or RT-PCR) could be referred to VOMC by their Emory provider or by calling the institutional COVID Hotline and hospitalized patients could be referred at discharge if within their isolation period. Patients in VOMC underwent standardized telemedicine assessment by Emory Healthcare providers as previously described (31). Care through VOMC continued for up to 21 days depending on symptom severity and risk factors for hospitalization. Our inclusion criteria were (a) adults at least 18 years of age, (b) previous positive test for SARS-CoV-2, (c) with a valid email address in the Emory electronic health record, and (d) discharge from the Emory VOMC.

Data collection

A quantitative, cross-sectional survey was created using Qualtrics® Online Survey Software (Qualtrics, Provo, UT) to collect participant-reported information on persistent COVID-19 symptoms and recall of acute symptoms. From August to November of 2020, an email was sent to eligible participants inviting them to complete the survey using an identified link. Non-

respondent patients were sent reminder emails and called once by study staff. The survey included research consent, general information (race, sex, education, income level), aspects of the participant's experience with SARS-CoV-2 infection such as severity of their acute disease, which symptoms were ongoing at the time of the survey (33 individual symptoms), questions related to physical and emotional quality of life, and access to healthcare. Specific symptoms of interest are listed in the results tables. Data on specific comorbidities (see results tables) and provider-assessed severity of acute illness at VOMC intake visit were extracted from the medical record for each participant. Provider-assessed severity was defined as "mild": cough without shortness of breath or wheeze and / or fever, chills and other mild systemic symptoms; "moderate": any mild symptoms plus dyspnea on exertion, wheezing and / or mid-chest tightness; "severe": shortness of breath at rest, pulse oximetry $\leq 92\%$, pleuritic pain and concerning systemic symptoms like syncope, severe weakness, confusion or acute decline in functional status (29,31). The survey was closed after three months of gathering responses.

Data analysis

Data from the survey were exported from Qualtrics into Microsoft Excel and analyzed using SAS v9.4 (Carey, NC). A p-value of 0.05 was considered statistically significant for all analyses. Summary statistics were reported using frequencies and means / medians where appropriate. Bivariate analyses using chi-sq, t-test or crude logistic regression (single variable) were performed between the main outcome (persistent symptoms), the main exposure (provider-assessed severity of acute illness) and all covariates. Covariates included age, sex, race, comorbid conditions, hospitalization, and income. Multivariate logistic regression was then

performed using any persistent symptom as an outcome with provider-assessed severity (mild versus moderate or severe) as the main exposure and age, sex, hospitalization and comorbidities as confounders. Tests of collinearity and interactions were performed and variables dropped if necessary. Backward stepwise elimination was then undertaken to determine the final model. A second model was conducted limited to participants who answered the survey at 90 days or greater.

In order to determine if certain categories of symptoms had unique associations with potential risk factors for persistence of these symptoms, we divided them into respiratory (dry or wet cough, dyspnea on exertion, shortness of breath at rest, chest tightness or pain), systemic (fatigue, chills, weakness, joint pains, muscle pains, dizziness), neuropsychiatric (headache, mental fog, difficulty sleeping, irritability, feeling depressed, feeling anxious), and loss of taste and/or smell. We then performed bivariate analyses with these outcomes and all main predictors as per the initial analyses above. Also compared to these categories of symptoms were individual rating of severity of acute symptoms related to that specific persistent symptom (like lower respiratory symptoms for persistent respiratory symptoms).

Multivariate logistic regression was performed for each category of symptom using the main exposure of provider rated illness severity and other covariates as listed above. Model diagnostics were also undertaken including testing of collinearity, interactions and confounding. Individual ratings of symptom severity were not included in the multivariate model.

Lastly, all symptoms were compared to measures of physical and emotional health to determine associations with persistent symptoms and three different self-reported markers of quality of physical and emotional health – whether they report their physical health as worse or much worse than before their COVID-19 (versus same or better), whether their physical health limits their daily activities, and whether their emotional health limits their daily activities (yes or no). Bivariate chi square analyses were performed with each symptom except for those persistent symptoms that were reported in less than 5 individuals.

Ethical Approvals

The study was approved by the Emory University Institutional Review Board. All participants provided electronic consent at the outset of the emailed survey.

Results

Basic descriptive factors

Two hundred ninety individuals consented and completed the questionnaire, of whom 216 (75%) were women and 194 (67.4%) reported a comorbid condition (Table 1). The median age was 44 (range 18, 84) and 125 (43.1%) were Black. The median length of time after diagnosis of their acute COVID-19 was 119 days (range 26, 220), with 70% responding at more than 90 days after their acute illness. Of the sample, 35 (12.6%) were hospitalized, and at the initial intake VOMC visit, 182 (68.7%) were determined to have mild or resolved symptoms, 81 (30.1%) moderate, and 2 (0.8%) severe. The most common comorbid condition was obesity ($\text{BMI} \geq 30 \text{ kg} / \text{m}^2$) followed by hypertension and asthma / COPD (Table 1). Half of the study sample

experienced self-reported weight loss during their illness with a mean loss of 10.7 lbs (SD 7.4) (Table 2). About 25% of individuals said their thinking was worse or much worse than before their acute COVID-19 illness and 25.6% said their physical health was somewhat or much worse than before their acute illness (Table 2).

Symptoms

Overall, 115 (39.7%) had persistent symptoms at the time of the survey (Supplemental Table 1). The most common persistent symptom was fatigue (n= 59, 20.3%) followed by dyspnea on exertion (n=41, 14.1%), and mental fog (n=39, 13.5%) (Supplemental Table 1). Table 3 shows the study sample split into two time periods: 26-90 days after the acute COVID-19 phase (“early,” about 1-3 months) and 90-220 days after the acute COVID-19 phase (“late,” over 3 months). There were similar proportions of patients with continued symptoms in the early group (n=34, 38.6%) and the late group (n=79, 39.9%), ($p = 0.84$). Twenty-nine symptoms are tabulated in table 3 and all of them were very similarly ranked in frequency whether the participant was in the early or late group. Loss of smell was common at 11.9% (n=33) even in the late group (n=21, 10.6%), twice as frequent as loss of taste (n=18, 6.3%). To account for the wide range of days post-COVID-19 that participants answered the survey, t-test analyses were performed for all symptoms based on days post-illness and did not show statistically significant differences based on when they took the survey.

Predictors of Persistent Symptoms

Since the two time periods (early and late) did not differ in the frequency of persistent symptoms or frequency of specific symptoms, we analyzed the study sample first in aggregate. In addition, we repeated the logistic regression model with only those “late” participants who answered the survey at 90 days or later from acute illness. Our main predicted exposure of moderate to severe disease severity at time of diagnosis (intake visit) was highly associated with persistent symptoms on both unadjusted and adjusted models (Table 4), with an aOR of 3.24 (95% CI 1.75, 6.02). This was similar in the 90 days and greater group. Being hospitalized was also more common in those with persistent symptoms but did not reach statistical significance on the adjusted logistic regression models. In the overall group, female sex was not statistically significantly associated with persistent symptoms, but when the model was limited to the late reporters, female sex (aOR 2.73, 95% CI 1.10, 6.79) was associated. Middle-age (aOR 2.08, 95% CI 1.07, 4.03) was associated with having persistent symptoms in both adjusted models. The only comorbid condition to have a significant result in the model was hypertension which had a negative association with persistent symptoms (aOR 0.45, 95% CI 0.22, 0.94), that remained when limited to the longer duration of symptoms (Table 4).

When persistent symptoms were divided into categories of symptoms (respiratory, neuropsychiatric, systemic, and loss of taste / smell), the provider-assessed severity at VOMC intake visit remained associated with these persistent symptoms (Table 5) in unadjusted bivariate analyses. Also included were individual patient rating of severity of acute symptoms (recall at time of survey) related to that specific persistent symptom (e.g. patient-rated severity of acute lower respiratory symptoms for persistent respiratory symptoms). Severe ratings for these were also consistently associated with the persistent chronic system-based symptoms.

Interestingly, comorbid lung disease was associated with persistent systemic symptoms (OR 2.18, 95% CI 1.13, 4.22) and taste / smell symptoms on bivariate analyses (OR 2.23, 95% CI 1.01, 4.94), but not with persistent respiratory symptoms (0.88, 95% CI 0.41, 1.90). These did not hold in the final logistic models, however. For those that reported moderate to severe taste and smell disturbance during their acute illness (n=190, 65.5%), 81% of those had resolution of their symptoms at the time of their completion of this survey (Table 5).

Symptoms associated with physical and mental health

Table 6 shows associations with individual symptoms and three different markers of quality of physical and emotional health. For physical health being worse than before acute COVID-19, the commonly reported persistent symptoms most associated were fatigue (OR 10.48, 95% CI 5.47, 20.07), muscle aches (OR 10.47, 95% CI 3.95, 27.81), weakness (OR 10.76, 95% CI 3.75, 30.84), feeling depressed (OR 10.35, 95% CI 4.14, 25.9) and mental fog (OR 9.82, 95% CI 4.63, 20.85). Although less commonly reported and with wide confidence intervals, joint pains (OR 17.1, 95% 5.56, 52.59) and shortness of breath at rest (OR 11.19, 95% CI 2.27, 55.18) had even stronger associations. For physical health limiting daily activities, the common symptoms most associated were dyspnea on exertion (OR 13.68, 95% CI 5.98, 31.28), mental fog (OR 12.41, 95% CI 5.41, 28.48), headache (OR 12.24, 95% CI 4.81, 31.17), and joint pains (OR 12.06, 95% CI 3.95, 36.85). While not a commonly reported symptom, heart palpitations (OR 16.17, 95% 4.62, 56.53) was strongly associated with limitations of daily activities. For emotional health limiting daily activities, the following symptoms were most associated: irritability (OR 6.02, 95% CI 2.02, 17.9), feeling depressed (OR 5.53, 95% CI 2.35, 12.99), back pain (OR 5.40, 95% CI 1.78,

16.32), feeling anxious (OR 4.71, 95% CI 1.78. 12.43), and ear fullness (OR 3.86, 95% 1.06, 14.04).

Discussion

Principal Findings

We find that chronic symptoms are common in a follow-up survey of patients previously enrolled in a COVID-19 outpatient telemedicine monitoring program, with 40% of patients reporting persistence of at least one symptom. We hypothesized based on prior work (29) that initial symptom severity (at time of telemedicine intake visit) would predict the likelihood of long-term symptoms and we find this association is significant. Patient recall of symptom severity (reported at time of survey) finds similar relation strengthening the internal validity of this finding. We do not find association between other factors such as demographics or comorbidities and the presence of symptoms at the time of follow-up survey except for female sex (increased likelihood) and hypertension (decreased likelihood), nor do we find a significant difference between patients responding to the survey closer to their acute illness versus those farther out from their acute illness.

The mechanism(s) underlying the persistence of symptoms beyond acute COVID-19 remain unclear; the finding of a relationship between the severity of acute symptoms (recorded at the end of the first week of illness) and the prevalence of symptoms months later suggests a possible role for acute inflammation and/or viral burden. Subsequent hospitalization may predict risk in the unadjusted comparison but is not significant in the adjusted model. This may

be due to the low number of hospitalizations in our cohort, but also that risk factors for hospitalization (age, male sex, comorbidities) are not directly associated with risk of long-term symptoms.

These findings are significant in public health messaging and individual risk communication for patients with COVID-19. The factors predicting persistent symptoms remain unclear and it appears that patients and the public cannot be reassured that individuals are unlikely to develop persistent symptoms until their initial course (i.e. first week of illness) is past. Furthermore, we do not find a difference in the frequency of persistent symptoms in our “early” (day 26-89) and “late” (day 90-220) groups. While it is possible that there are differences between these groups based on the “wave” of the pandemic, it suggests that there is not a clear time for expected resolution of symptoms that persist, and further study will be needed to determine long-term outcomes.

Many respondents to the survey reported lower quality of life on questions regarding limitations due to physical and emotional health, similar to a prior report indicating disrupted home, work, and social life for patients after acute COVID-19(6). These responses were associated with certain common symptoms (e.g. fatigue, dyspnea on exertion, mental fog) more than others (e.g. cough, change in smell or taste). These findings may suggest that specific symptom profiles are more significant in quality of life and may warrant particular emphasis in studies of PASC. More than half sought care for their symptoms indicating a level of concern leading to medical attention. Prior work indicates that patients encounter challenges due to

limited recognition of PASC (5,32) and providers should be aware of the likelihood of PASC and evolving treatment guidelines.

Comparison to prior studies

Similar to previous studies (23,25–27,33,34), this study represents a single institution report of persistent symptoms in patients after acute COVID-19 and finds a high rate of persistent symptoms. A novel aspect of this work is the prospective enrollment in the telemedicine program with standardized data collection by providers in the acute phase of illness, such that risk factors for later outcomes could be systematically analyzed. We found that the severity of symptoms at the time of the acute telemedicine visit was a significant predictor, which corroborates the prior reports relating acute illness profile to prolonged symptoms (24–26). We do not find a strong association with hospitalization, suggesting that the term “severity” may need further clarification as a symptom descriptor distinct from “disease severity” (often referring to highest level of care, which is more strongly associated with age, sex, and medical comorbidity). The use of the physical health questions also gives more description and nuance to our findings, which is an added strength over large cohort studies of reported frequency of persistent symptoms.

We find that female gender is associated with PASC in our cohort, especially in the later group, similar to prior studies (23–25). It is well described that males are at higher risk for severe acute COVID-19 (35), and it has been proposed that genetic differences (including expression of Toll-like receptor 7 on the X chromosome) may account for this(36), but a mechanism relating to

increased risk for PASC is not clear. There may be a common mechanism with other post-infectious syndromes: female gender has been reported as associated with lower six minute walk distance in survivors of SARS (9) as well higher rate of post-dengue fatigue (13), post-chikungunya arthralgia (12) but not consistently for post-Ebola symptoms(11).

Middle age (40-59) was significant in the adjusted model, similar to prior report (26). Given the strong association of illness severity (i.e. risk of hospitalization and death) with age(35), hypothesized to relate to immune system changes across age groups(36), it is plausible that immune-system mediated factors during acute illness increase the risk for PASC in individuals in middle age more than other age categories.

The role of hypertension in acute COVID-19 is not clear - initially reported as a possible risk factor for severe COVID-19 (in excess in severe versus nonsevere cases)(37) , has not been shown to be a robust predictor of severity with age-hypertension interactions even decreasing risk(35) and improved blood pressure control correlating to worse outcomes (38).

Antihypertensive medications may impact disease course, with preliminary results indicating effects that may vary by race(39). In this context, it is possible that there is a blood pressure (or antihypertensive) correlation with PASC and this relationship merits further study.

Limitations

This report was conducted within a specific cohort (outpatient telemedicine clinic in Atlanta, Georgia) early in the COVID-19 pandemic. To enter this cohort, patients must have had symptoms consistent with COVID-19 and consented to telemedicine visit – few asymptomatic (or minimally symptomatic) patients are represented and the number of hospitalized patients is relatively small, thus limiting generalizability. A related concern is response bias, with a relatively low response rate to the survey. However, we did not indicate the purpose of the survey in the invitation email and consent and do not have reason to believe respondents would be more symptomatic than non-respondents. A third consideration interpreting our results is the uncertainty regarding the definition and grading of PASC. This was not a known entity at the time of survey design and the questions addressed the presence of ongoing symptoms and overall health-related quality of life, but not the impact of individual symptoms on functional status. For this reason, we have analyzed the association of symptoms with functional limitations (Table 5) as a prompt for further study.

Future study is needed to clarify the risk factors, mechanisms, duration, and subtypes of PASC. This preliminary work indicates that there are features of acute COVID-19 that may be predictive and prospective study including objective measure (e.g. inflammatory markers) as well as patient-reported measures (e.g. symptom severity) may clarify this further. We find a high rate of PASC in an outpatient cohort with impact on many individuals quality of life and ongoing follow-up for this important entity is warranted.

MANUSCRIPT INFORMATION

Funding

This work was supported by the Georgia Geriatrics Workforce Enhancement Program COVID-19 Telehealth award, which is supported by the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) as part of award number T1MHP39056 totaling US \$90,625, with 0% financed with non-governmental sources. The contents of this paper are those of the authors and do not necessarily represent the official views of, nor an endorsement by, the HRSA, the HHS, or the US Government.

Acknowledgments

We would like to acknowledge Elizabeth Harrell for data retrieval for this work. We also acknowledge the members of the Virtual Outpatient Management Clinic at Emory Healthcare, including faculty, staff, and administrative members of the Paul W Seavey Comprehensive Internal Medicine Clinic and the Emory at Rockbridge Primary Care clinic, as well as the physicians, nurses, and APPs who volunteered from other sites.

Conflicts of Interest

JO received grant funding from Regeneron Pharmaceuticals, Inc. for a study of Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts unrelated to this work.

References

1. Hick JL, Biddinger PD. Novel Coronavirus and Old Lessons — Preparing the Health System for the Pandemic. *N Engl J Med*. 2020 May 14;382(20):e55.
2. Callard F, Perego E. How and why patients made Long Covid. *Soc Sci Med*. 2021 Jan 1;268:113426.
3. Carfi A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*. 2020 Aug 11;324(6):603–5.
4. Tenforde MW. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. *MMWR Morb Mortal Wkly Rep* [Internet]. 2020 [cited 2021 Feb 13];69. Available from: <https://www.cdc.gov/mmwr/volumes/69/wr/mm6930e1.htm>
5. Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, et al. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. *BMC Health Serv Res*. 2020 Dec 20;20(1):1144.
6. Havervall S, Rosell A, Phillipson M, Mangsbo SM, Nilsson P, Hober S, et al. Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers. *JAMA* [Internet]. 2021 Apr 7 [cited 2021 Apr 12]; Available from: <https://jamanetwork.com/journals/jama/fullarticle/2778528>

7. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. *JAMA Netw Open*. 2021 Feb 19;4(2):e210830.
8. Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers.” *Ann Clin Transl Neurol* [Internet]. [cited 2021 Mar 24];n/a(n/a). Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/acn3.51350>
9. Ngai JC, Ko FW, Ng SS, To K, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. *Respirol Carlton Vic*. 2010 Apr;15(3):543–50.
10. Lam MH-B. Mental Morbidities and Chronic Fatigue in Severe Acute Respiratory Syndrome Survivors: Long-term Follow-up. *Arch Intern Med*. 2009 Dec 14;169(22):2142.
11. Scott JT, Sesay FR, Massaquoi TA, Idriss BR, Sahr F, Semple MG. Post-Ebola Syndrome, Sierra Leone. *Emerg Infect Dis*. 2016 Apr;22(4):641–6.
12. Win MK, Chow A, Dimatatac F, Go CJ, Leo YS. Chikungunya fever in Singapore: Acute clinical and laboratory features, and factors associated with persistent arthralgia. *J Clin Virol*. 2010 Oct 1;49(2):111–4.
13. Sigera PC, Rajapakse S, Weeratunga P, De Silva NL, Gomes L, Malavige GN, et al. Dengue and post-infection fatigue: findings from a prospective cohort-the Colombo Dengue Study. *Trans R Soc Trop Med Hyg*. 2020 Oct 24;
14. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: An Overview and Approach to Classification. *Open Forum Infect Dis*. 2020 Dec 1;7(12):ofaa509.
15. Greenhalgh T, Knight M, A’Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. *BMJ*. 2020 Aug 11;370:m3026.
16. Doykov I, Hällqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. “The long tail of Covid-19” - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. *F1000Research*. 2020;9:1349.
17. Zhao Y-M, Shang Y-M, Song W-B, Li Q-Q, Xie H, Xu Q-F, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. *EClinicalMedicine*. 2020 Aug;25:100463.
18. Paneroni M, Simonelli C, Saleri M, Bertacchini L, Venturelli M, Troosters T, et al. Muscle Strength and Physical Performance in Patients Without Previous Disabilities Recovering From COVID-19 Pneumonia. *Am J Phys Med Rehabil*. 2021 Feb;100(2):105–9.

19. Raman B, Cassar MP, Tunnicliffe EM, Filippini N, Griffanti L, Alfaro-Almagro F, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. medRxiv. 2020 Jan 1;2020.10.15.20205054.
20. Guedj E, Campion JY, Dudouet P, Kaphan E, Bregeon F, Tissot-Dupont H, et al. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging [Internet]. 2021 Jan 26 [cited 2021 Feb 13]; Available from: <https://doi.org/10.1007/s00259-021-05215-4>
21. Dennis A, Wamil M, Kapur S, Alberts J, Badley AD, Decker GA, et al. Multi-organ impairment in low-risk individuals with long COVID. medRxiv. 2020 Jan 1;2020.10.14.20212555.
22. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv. 2021 Jan 29;2021.01.27.21250617.
23. Bliddal S, Banasik K, Pedersen OB, Nissen I, Cantwell L, Schwinn M, et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. medRxiv. 2021 Jan 25;2021.01.22.21249945.
24. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med [Internet]. 2021 Mar 10 [cited 2021 Mar 29]; Available from: <http://www.nature.com/articles/s41591-021-01292-y>
25. Walsh-Messinger J, Manis H, Vrabec A, Sizemore J, Bishof K, Debidia M, et al. The Kids Are Not Alright: A Preliminary Report of Post-COVID Syndrome in University Students. medRxiv. 2020 Nov 29;2020.11.24.20238261.
26. Carvalho-Schneider C, Laurent E, Lemaignan A, Beauvils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect [Internet]. 2020 Oct 5 [cited 2021 Feb 14];0(0). Available from: [https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X\(20\)30606-6/abstract](https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(20)30606-6/abstract)
27. Petersen MS, Kristiansen MF, Hanusson KD, Danielsen ME, Á Steig B, Gaini S, et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020 Nov 30;
28. Moreno-Pérez O, Merino E, Leon-Ramirez J-M, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect [Internet]. [cited 2021 Feb 13]; Available from: <https://doi.org/10.1016/j.jinf.2021.01.004>

29. O'Keefe JB, Tong EJ, O'Keefe GD, Tong DC. Description of symptom course in a telemedicine monitoring clinic for acute symptomatic COVID-19: a retrospective cohort study. *BMJ Open*. 2021 Mar 1;11(3):e044154.
30. Cellai M, O'Keefe JB. Characterization of Prolonged COVID-19 Symptoms in an Outpatient Telemedicine Clinic. *Open Forum Infect Dis* [Internet]. 2020 Oct 1 [cited 2021 Feb 13];7(ofaa420). Available from: <https://doi.org/10.1093/ofid/ofaa420>
31. O'Keefe JB, Tong EJ, Taylor TH, O'Keefe GAD, Tong DC. Use of a Telemedicine Risk Assessment Tool to Predict the Risk of Hospitalization of 496 Outpatients with COVID-19: Retrospective Analysis. *JMIR Public Health Surveill*. 2021 Feb 26;
32. Siegelman JN. Reflections of a COVID-19 Long Hauler. *JAMA*. 2020 Nov 24;324(20):2031.
33. Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. *PLOS ONE*. 2020 Nov 9;15(11):e0240784.
34. Jacobson KB, Rao M, Bonilla H, Subramanian A, Hack I, Madrigal M, et al. Patients with uncomplicated COVID-19 have long-term persistent symptoms and functional impairment similar to patients with severe COVID-19: a cautionary tale during a global pandemic. *Clin Infect Dis*. 2021 Feb 7;ciab103.
35. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. *Nature*. 2020 Aug;584(7821):430–6.
36. Brodin P. Immune determinants of COVID-19 disease presentation and severity. *Nat Med*. 2021 Jan;27(1):28–33.
37. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* [Internet]. 2020 Feb 28 [cited 2021 Mar 27]; Available from: <https://www.nejm.org/doi/10.1056/NEJMoa2002032>
38. Sheppard James P., Nicholson Brian D., Lee Joseph, McGagh Dylan, Sherlock Julian, Koshari Constantinos, et al. Association Between Blood Pressure Control and Coronavirus Disease 2019 Outcomes in 45 418 Symptomatic Patients With Hypertension. *Hypertension*. 2021 Mar 3;77(3):846–55.
39. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. *Heart*. 2020 Oct 1;106(19):1503–11.

Table 1. Basic demographics and baseline factors for persistent symptoms versus no persistent symptoms at time of survey (ranging 1-7 months post-acute illness). Table 6 has these broken down by early (<90 days) and late ($\geq$ 90 days).

	Persistent symptoms n=115	No persistent symptoms n=175	Total n=290
Age, years; median (range)	46 (20, 84)	40 (18, 83)	44 (18, 84)
Sex ⁱ , n (%)			
Male	22 (19.3)	50 (28.7)	72 (25)
Female	92 (80.7)	124 (71.3)	216 (75)
Race / Ethnicity ⁱⁱ , n (%)			
White	50 (44.6)	70 (41.4)	120 (42.7)
Black	46 (41.1)	79 (46.8)	125 (44.5)
Hispanic / Latinx	9 (5.3)	4 (3.6)	13 (4.6)
Asian	6 (5.4)	6 (3.6)	12 (4.3)
Native Hawaiian, Pacific Islander	0 (0)	1 (0.6)	1 (0.4)
Other	4 (2.4)	6 (5.4)	10 (3.6)
Provider rated moderate – severe dx ⁱⁱⁱ , n (%)	51 (48.1)	32 (20.1)	83 (31.3)
Hospitalized ^{iv} , n (%)	20 (18.4)	15 (8.9)	35 (12.6)
Any Comorbidity ⁺ , n (%)	76 (67.3)	118 (67.4)	194 (67.4)

Lung disease*	24 (23.5)	25 (16)	49 (19)
Obesity	54 (47.8)	81 (46.3)	113 (39.2)
Hypertension	27 (26.5)	47 (30.1)	74 (28.7)
Heart disease^	7 (6.9)	9 (5.8)	16 (6.2)
Cancer	6 (5.9)	15 (9.6)	21 (8.1)
Diabetes	11 (10.8)	14 (9.0)	25 (9.7)
Immune suppression	12 (11.8)	19 (12.2)	31 (12)
Kidney disease	5 (4.9)	3 (1.9)	8 (3.1)
Income^v			
Less than \$30,000	8 (7.5)	24 (15.4)	32 (12.2)
\$30,000-\$60,000	32 (29.9)	54 (36.6)	86 (32.7)
\$60,000 - \$100,000	31 (29.0)	34 (21.8)	65 (24.7)
Over \$100,000 (ref)	36 (33.6)	44 (28.2)	80 (30.4)

*Defined as asthma, COPD or other chronic lung disease; ^Defined as coronary artery disease or heart failure

Defined as biologic or other immunosuppressive medications including chronic corticosteroid at ≥ 20 mg prednisone daily, detectable HIV VL or CD4 count < 200 cells/mm³ or other specified immunodeficiency.

ⁱ Available for 288 participants; ⁱⁱ Available for 281 participants; ⁱⁱⁱ Available for 265 participants; ^{iv} Available for 278 participants; ^v Available for 263 participants; *Comorbidities available for 258 participants except for obesity, which is available for 288.

Table 2. Other characteristics of study survey responses.

Other survey variables	n (%) unless otherwise noted
Weight loss, n (%)	132 (50.2)
If yes, average lbs lost (SD)	10.7 (7.4)
Sought care for persistent symptoms (n = 113)	
No	51 (46.0)
Primary Care	39 (34.5)
Specialist	12 (10.6)
Urgent care	1 (.0)
Two or more (i.e. urgent care and primary care)	9 (8.0)
Thinking /memory presently	
Excellent	74 (25.6)
Very good	87 (30.1)
Good	78 (27.0)
Fair	42 (14.5)
Poor	8 (2.8)
Compared to before COVID-19, how are thinking & memory:	
Much better now	9 (3.1)
Better now	8 (2.8)

About the same	198 (68.5)
Worse now	69 (23.9)
Much worse now	5 (1.7)
Physical health compared to prior to COVID-19 illness	
Much better	22 (7.7)
Somewhat better	35 (12.2)
About the same	156 (54.6)
Somewhat worse	62 (21.7)
Much worse	11 (3.9)
Physical Health affects daily activities	
Yes	90 (31.4)
Emotional health affects daily activities	
Yes	83 (29.1)

Table 3. Descriptive variables stratified by time since acute-COVID-19 illness. P-value shown based on chi-sq or t-test where appropriate, significant values <0.05. Table based on 286 participants as 4 were missing dates of acute illness.

.	26-89 (median 61) days post	90-220 (median 139) days post	Total n=286	p-value

	acute COVID-19 n=88	acute COVID-19 n=198		
Age, mean (SD)	46 (16)	45 (14)	45 (15)	0.35
Female sex	67 (76.1)	147 (74.2)	214 (74.8)	0.73
Race^ (279)				
White	41 (47.7)	79 (40.9)	120 (43)	0.26
Black / African American	33 (38.4)	90 (46.6)	123 (44.1)	
Hispanic / Latinx	3 (3.5)	10 (5.2)	13 (4.7)	
Asian	3 (3.5)	9 (4.7)	12 (4.3)	
Native Hawaiian / Pacific Islander	0	1 (0.5)	1 (0.4)	
Other	6 (7)	4 (2.1)	10 (3.6)	
Hospitalized	9 (10.6)	25 (13.3)	34 (12.4)	0.54
Provider Defined Disease Severity*				
Mild	56 (67.5)	126 (69.2)	182 (68.7)	0.78
Moderate	27 (32.5)	54 (29.7)	81 (30.6)	
Severe	0	2 (1.1)	2 (0.8)	
Persistent symptoms				
Any	34 (38.6)	79 (39.9)	113 (39.5)	0.84
Fatigue	17 (19.3)	42 (21.2)	59 (20.6)	0.71
Dyspnea on exertion	16 (18.2)	25 (12.6)	41 (14.3)	0.22

Mental fog	12 (13.6)	27 (13.6)	39 (13.6)	1.0
Difficulty sleeping	10 (11.4)	22 (11.1)	32 (11.2)	0.95
Loss of smell	12 (13.6)	21 (10.6)	33 (11.5)	0.46
Headache	8 (9.1)	23 (11.6)	31 (10.8)	0.53
Dry cough	8 (9.1)	17 (8.6)	25 (8.7)	0.89
Feeling depressed	7 (8.0)	19 (9.6)	26 (9.1)	0.66
Muscle aches	7 (8.0)	17 (8.6)	24 (8.4)	0.86
Joint pains	6 (6.8)	16 (8.1)	22 (7.7)	0.71
Weakness	9 (10.2)	12 (6.1)	21 (7.3)	0.21
Heart palpitations	5 (5.7)	16 (8.1)	21 (7.3)	0.47
Anxiety / nervousness	4 (4.6)	15 (7.6)	19 (6.6)	0.34
Chest tightness / pain	6 (6.8)	13 (6.6)	19 (6.6)	0.94
Loss / change in taste	7 (8.0)	11 (5.6)	18 (6.3)	0.44
Sinus congestion	4 (4.6)	13 (6.6)	17 (5.9)	0.51
Irritability	5 (5.7)	11 (5.7)	16 (5.7)	0.97
Back pain	4 (4.6)	11 (5.6)	15 (5.2)	0.72
Dizziness	3 (3.5)	8 (4.0)	12 (4.2)	0.84
Rhinorrhea	2 (2.3)	9 (4.6)	11 (3.9)	0.36
Ear fullness	2 (2.3)	8 (4.0)	10 (3.5)	0.45
Heartburn	2 (2.3)	8 (4.0)	10 (3.5)	0.45
Shortness of breath at rest	2 (2.3)	7 (3.5)	9 (3.2)	0.57

Nausea	1 (1.1)	4 (2.0)	5 (1.8)	0.60
Rash	1 (1.1)	3 (1.5)	4 (1.4)	0.80
Abdominal pain	0 (0)	4 (2.0)	4 (1.4)	0.18
Chills	1 (1.1)	2 (1.0)	3 (1.1)	0.92
Sore throat	1 (1.1)	1 (0.5)	2 (0.7)	0.55
Diarrhea	0 (0)	2 (1.0)	2 (0.7)	0.34
Loss of appetite	1 (1.1)	0 (0)	1 (0.4)	--
Other symptoms	3 (3.4)	11 (5.6)	14 (4.9)	0.44

^available for 279 participants; *available for 265 participants

Table 4. Bivariate analyses and multivariate logistic regression showing unadjusted and adjusted odds ratio respectively for the outcome of persistent symptoms, with moderate-severe acute illness as the main exposure. Bolded values are significant with a p-value of <0.05.

Variable	Persistent Symptoms OR	95% CI	Adjusted OR	95% CI	aOR limited to >90 days	95% CI
Provider rated moderate – severe dx (265)	3.68	2.14, 6.34	3.24	1.75, 6.02	3.00	1.40, 6.41
Hospitalized (278)	2.31	1.12, 4.73	2.22	0.82, 6.07	2.15	0.66, 7.02

Age						
18-39	1 (ref)				1	
40-59	1.89	1.11, 3.21	2.08	1.07, 4.03	2.24	1.01, 4.95
60 and over	1.36	0.70, 2.65	1.80	0.77, 4.20	1.85	0.60, 5.74
Sex (288)						
Male	1 (ref)		1		1	
Female	1.69	0.95, 2.98	1.99	0.98, 4.04	2.73	1.10, 6.79
Race / Ethnicity			-----	-----		
White	1 (ref)					
Black	0.82	0.49, 1.36				
Latinx	0.62	0.18, 2.13				
Asian	1.40	0.43, 4.59				
Other	1.68	0.49, 5.81				
Co-morbidity						
(ref: no co-morbidity)						
Any	0.99	0.60, 1.64	---			
Obesity	1.06	0.66, 1.71	---			
HTN	0.84	0.48, 1.46	0.45	0.22, 0.94	0.33	0.13, 0.82
Lung disease	1.61	0.86, 3.02	1.26	0.62, 2.55	1.30	0.55, 3.08
Heart disease	1.20	0.43, 3.34	1.29	0.39, 4.65	0.97	0.12, 7.59

Diabetes	1.23	0.53, 2.82	---			
Cancer	0.59	0.22, 1.57	---			
Immune suppression	0.96	0.45, 2.08	---			
Renal disease	2.63	0.61, 11.25	---			
Annual Income						
Less than \$30,000	0.41	0.16, 1.02	--			
\$30,000-\$60,000	0.72	0.39, 1.35	--			
\$60,000 - \$100,000	1.11	0.58, 2.15				
Over \$100,000 (ref)	1	----				

Table 5. Bivariate and adjusted analyses of associated between specific groupings of persistent symptoms broken down by system. Self-rated *acute illness* symptom severity of the same organ symptom also included as a predictor.

Symptoms by system	Bivariate associations	Adjusted model

Respiratory Symptoms	Persistent n=68	Not persistent n=222	OR	95% CI	aOR	95% CI
Provider rated moderate-severe acute illness	32 (38.6)	51 (61.5)	3.00	1.65, 5.78	2.85	1.43, 5.60
Hospitalized	16 (24.6)	19 (8.9)	3.33	1.60, 6.95	3.17	1.20, 8.36
Self-rated symptom severity during acute COVID-19:						
Lower respiratory						
None or mild	10 (14.7)	117 (52.7)	1		---	
Mod or severe	58 (85.3)	105 (47.3)	6.46	3.14, 13.29		
Sex						
Male	13 (19.1)	58 (27.4)	1			
Female	55 (80.9)	154 (72.6)	1.59	0.81, 3.13	1.52	0.68, 3.37
Age						
18-39	14 (20.6)	98 (40.5)	1	1	1	
40-59	30 (45.5)	73 (35.6)	1.68	0.91, 3.12	1.37	0.65, 2.92
60 and over	12 (18.2)	34 (16.7)	1.44	0.65, 3.19	1.11	0.42, 2.92
Any comorbidity	48 (78.7)	146 (69.9)	1.59	0.81, 3.15	-----	
Lung disease	10 (17.5)	39 (19.4)	0.88	0.41, 1.90	0.55	0.23, 1.28
Obesity	36 (26.7)	99 (44.8)	1.43	0.83, 2.48		
Hypertension	21 (36.8)	52 (25.9)	1.67	0.90, 3.12	1.32	0.62, 2.81

Heart disease	4 (7.0)	12 (6.0)	1.19	0.37, 3.84		
Cancer	6 (10.5)	15 (7.5)	1.46	0.54, 3.95		
Diabetes	8 (14.0)	17 (8.5)	1.77	0.72, 4.33		
Immune suppression	9 (15.8)	22 (11.0)	1.53	0.66, 3.53		
Systemic Symptoms	Persistent	Not persistent				
	n=74	n= 216				
Provider rated moderate-severe acute COVID-19 illness	37 (52.9)	46 (23.6)	3.63	2.05, 6.45	2.78	1.46, 5.32
Hospitalized	14 (19.7)	21 (10.1)	2.17	1.04, 4.55	1.62	0.61, 4.33
Self-rated symptom severity during acute COVID-19:						
General / systemic						
None or mild	5 (6.8)	72 (33.3)	1		--	
Moderate or severe	69 (93.2)	144 (66.7)	6.90	2.67, 17.86		
Sex						
Male	16 (21.6)	56 (26.2)	1		1	
Female	58 (78.4)	158 (73.8)	1.28	0.68, 2.42	1.27	0.59, 2.72
Age						
18-39	23 (31.1)	103 (48.1)	1		1	
40-59	36 (48.7)	73 (34.1)	2.21	1.21, 4.04	1.98	0.96, 4.10

60 and over	15 (20.3)	38 (17.8)	1.77	0.84, 3.74	1.99	0.79, 5.02
Any comorbidity, 288	52 (70.3)	142 (66.4)	1.20	0.68, 2.13	--	
Lung disease, 258	19 (28.8)	30 (15.6)	2.18	1.13, 4.22	1.68	0.82, 3.47
Obesity, 288	40 (54.1)	95 (44.4)	1.47	0.87, 2.51	1.28	0.66, 2.48
Hypertension, 258	20 (30.3)	53 (27.6)	1.14	0.62, 2.11	0.65	0.31, 1.40
Heart disease	5 (7.6)	11 (5.7)	1.35	0.45, 4.04	---	
Cancer	4 (6.1)	17 (8.9)	0.66	0.22, 2.05	---	
Diabetes , 258	8 (12.2)	17 (8.9)	1.42	0.58, 3.46	---	
Immune suppression (n=258)	10 (15.1)	21 (10.9)	1.45	0.65, 3.27	---	
Neuropsychiatric Symptoms	Persistent n=79	Not persistent n=211				
Provider rated moderate-severe illness	41 (55.4)	42 (22)	4.41	2.49, 7.81	4.06	2.11, 7.81
Hospitalized	17 (22.1)	18 (9)	2.90	1.40, 5.94	3.15	1.15, 8.68
Self-rated symptom severity during acute COVID-19:						
General / systemic						
None or mild	7 (8.9)	70 (33.2)	1	--		
Moderate or severe	72 (91.1)	141 (66.8)	5.11	2.23, 11.68	----	

Sex						
Male	15 (19)	57 (27.3)	1		1	
Female	64 (81.0)	152 (72.7)	1.6	0.84, 3.03	1.53	0.70, 3.36
Age						
18-39	27 (34.2)	99 (47.4)	1		1	
40-59	37 (46.8)	72 (34.4)	1.88	1.05, 3.37	1.70	0.82, 3.51
60 and over	15 (19)	38 (18.2)	1.45	0.70, 3.01	1.36	0.52, 3.53
Any comorbidity	55 (69.6)	139 (66.5)	1.15	0.66, 2.02	---	
Lung disease	17 (24.6)	32 (16.9)	1.60	0.82, 3.12	0.96	0.45, 2.07
Obesity	43 (54.4)	92 (44.0)	1.52	0.90, 2.56	1.13	0.58, 2.20
Hypertension	20 (29)	54 (28.6)	1.02	0.56, 1.87	0.56	0.25, 1.28
Heart disease	6 (8.7)	10 (5.3.)	1.71	0.59, 4.88	----	---
Cancer	5 (7.3)	16 (8.5)	0.85	0.30, 2.40	----	----
Diabetes	10 (14.5)	15 (7.9)	2.0	0.84, 4.61	2.20	0.74, 6.59
Immune suppression	9 (13)	22 (11.6)	1.14	0.50, 2.61	-----	---
Loss of taste / smell	Persistent	Not persistent				
	n=37	n=253				
Provider rated moderate-severe acute illness	17 (48.6)	66 (28.7)	2.37	1.14, 4.83	2.35	1.08, 5.11
Hospitalized	2 (5.71)	33 (13.6)	---	-----	----	----

Self-rated symptom severity during acute COVID-19						
Taste / smell disturbance:						
None or mild	1 (2.7)	99 (39.1)	1			
Moderate or severe	36 (97.3)	154 (60.8)	23.1	3.12, 171.51		
Sex	30 (80.1)	186 (74.1)	1.50	0.63, 3.57	1.29	0.51, 3.26
Age						
18-39	12 (32.4)	114 (45.4)	1		1	
40-59	20 (54.1)	89 (35.5)	2.14	0.99, 4.60	1.79	0.76, 4.21
60 and over	5 (13.5)	48 (19.1)	0.99	0.33, 2.96	1.02	0.31, 3.39
Any comorbidity	25 (67.6)	169 (67.3)	1.01	0.48, 2.11	--	
Lung disease	11 (31.4)	38 (17)	2.23	1.01, 4.94	1.90	0.82, 4.41
Obesity	18 (48.7)	117 (46.6)	1.09	0.54, 2.16	1.02	0.46, 2.26
Hypertension	9 (25.7)	65 (29.2)	0.84	0.37, 1.89	0.72	0.28, 1.83
Heart disease	3 (8.6)	13 (5.8)	1.51	0.41, 5.61	--	
Diabetes	3 (8.6)	22 (9.9)	0.86	0.24, 3.03	--	
Immune suppression	5 (14.3)	26 (11.7)	1.26	0.45, 3.54	--	

Table 6. Associations, measured by odds ratios, and 95% confidence intervals, between individual persistent symptoms and physical and emotional health indicators. Limited to symptoms that were reported by at least 5 participants.

Persistent symptoms	Physical health worse than before acute COVID-19	Physical health affects daily activities	Emotional health affects daily activities
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Fatigue	10.48 (5.47, 20.07)	10.35 (5.36, 19.98)	2.56 (1.41, 4.64)
Dyspnea on exertion	8.34 (4.06, 17.15)	13.68 (5.98, 31.28)	2.16 (1.09, 4.25)
Mental fog	9.83 (4.63, 20.85)	12.41 (5.41, 28.48)	3.06 (1.53, 6.10)
Difficulty sleeping	7.42 (3.36, 16.35)	7.17 (3.16, 16.27)	3.21 (1.52, 6.79)
Loss of smell	4.32 (2.05, 9.12)	4.69 (2.19, 10.05)	1.46 (0.68, 3.12)
Headache	3.99 (1.84, 8.66)	12.24 (4.81, 31.17)	3.46 (1.62, 7.40)
Dry cough	2.34 (1.02, 5.36)	2.01 (0.89, 4.54)	1.09 (0.45, 2.62)
Feeling depressed	10.35 (4.14, 25.9)	7.26 (2.93, 18.02)	5.53 (2.35, 12.99)
Muscle aches	10.47 (3.95, 27.81)	6.32 (2.52, 15.87)	2.68 (1.15, 6.23)
Joint pains	17.1 (5.56, 52.59)	12.06 (3.95, 36.85)	1.77 (0.73, 4.31)
Weakness	10.76 (3.75, 30.84)	11.24 (3.66, 34.51)	1.55 (0.62, 3.89)
Heart palpitations	4.46 (1.79, 11.08)	16.17 (4.62, 56.53)	2.38 (0.97, 5.84)
Anxiety / nervousness	3.60 (1.40, 9.25)	7.07 (2.46, 20.32)	4.71 (1.78, 12.43)
Chest tightness / pain	7.48 (2.73, 20.51)	5.38 (1.97, 14.65)	1.85 (0.72, 4.79)
Loss / change in taste	4.67 (1.71, 12.78)	2.95 (1.12, 7.76)	1.60 (0.60, 4.28)

Sinus congestion	2.79 (1.03, 7.53)	5.91 (2.01, 17.32)	1.77 (0.65, 4.82)
Irritability	3.15 (1.14, 8.74)	7.42 (2.32, 23.72)	6.02 (2.02, 17.9)
Back pain	4.85 (1.66, 14.15)	9.95 (2.73, 36.22)	5.40 (1.78, 16.32)
Dizziness	6.43 (1.88, 22.05)	7.19 (1.90, 27.22)	3.63 (1.12, 11.78)
Rhinorrhea	3.73 (1.10, 12.60)	6.31 (1.63, 24.37)	2.09 (0.62, 7.06)
Ear fullness	4.68 (1.28, 17.08)	9.51 (1.98, 45.76)	3.86 (1.06, 14.04)
Heartburn	3.06 (0.86, 10.89)	5.45 (1.38, 21.61)	2.53 (0.71, 8.97)
Shortness of breath at rest	11.19 (2.27, 55.18)	4.62 (1.13, 18.91)	1.23 (0.30, 5.02)